AGIOS PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
AGIO$31.38+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (In thousands, except share and per share data) December 31: | 2024 | 2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $76,247 | $88,205 |
| Marketable securities | 817,463 | 688,723 |
| Accounts receivable, net | 4,109 | 2,810 |
| Inventory | 27,616 | 19,076 |
| Prepaid expenses and other current assets | 40,165 | 35,021 |
| Total current assets | 965,600 | 833,835 |
| Marketable securities | 638,321 | 29,435 |
| Operating lease assets | 42,879 | 54,409 |
| Property and equipment, net | 11,675 | 15,382 |
| Other non-current assets | 4,724 | 4,057 |
| Total assets | $1,663,199 | $937,118 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $16,643 | $9,780 |
| Accrued expenses | 46,861 | 43,167 |
| Income taxes payable | 871 | — |
| Operating lease liabilities | 16,781 | 15,008 |
| Total current liabilities | 81,156 | 67,955 |
| Operating lease liabilities, net of current portion | 40,207 | 56,988 |
| Other non-current liabilities | 880 | 1,156 |
| Total liabilities | 122,243 | 126,099 |
| Commitments and contingent liabilities (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 73,372,696 shares issued and 57,156,285 outstanding at December 31, 2024 and 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 | 73 | 72 |
| Additional paid-in capital | 2,493,811 | 2,436,523 |
| Accumulated other comprehensive loss | (1,518) | (441) |
| Accumulated deficit | (148,924) | (822,649) |
| Treasury stock, at cost (16,216,411 shares at December 31, 2024 and December 31, 2023) | (802,486) | (802,486) |
| Total stockholders’ equity | 1,540,956 | 811,019 |
| Total liabilities and stockholders’ equity | $1,663,199 | $937,118 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.